Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab + Neoadjuvant Hormone Therapy in High-Risk Prostate Cancer
NCT00075192Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2004
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tremelimumab in prostate cancer (PCa), sponsored by AstraZeneca. Started Mar 2004; status: completed.
02
Drugs
tremelimumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00075192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00075192.